PaxVax, a specialty vaccine company focused on travel and biodefense, has acquired the oral typhoid vaccine Vivotif from Crucell Switzerland AG, as well as its manufacturing facility in Thörishaus, near Bern, Switzerland. Additionally, PaxVax is acquiring marketing, sales, and distribution capabilities in select markets including the United States, and certain other assets related to travel vaccines such as hepatitis A. Financial terms of the transaction were not disclosed.

Through this acquisition, PaxVax assumes manufacturing, sales, regulatory, and distribution responsibilities related to the global supply of Vivotif, including approximately 80 employees worldwide. Vivotif was approved by the US Food and Drug Administration in 1989 and is currently approved for sale in 27 countries. Financing for the transaction was provided by an investment fund managed by Pharmakon Advisors.

​Vivotif is a live attenuated typhoid fever vaccine for oral administration. It is the only oral vaccine indicated for use against Salmonella typhi, the most prevalent of the typhoid fever-causing bacteria. The vaccine is indicated for adults and children over the age of six.

PaxVax is headquartered in Redwood City, California and maintains research and development GMP facilities in San Diego, California.

Source: PaxVax